Relief Therapeutics Releases 2025 Half-Year Report

Relief Therapeutics Holding SA has published its 2025 half-year report, highlighting key advancements in its biopharmaceutical endeavors. RLF-TD011, a lead wound care candidate, received Rare Pediatric Disease designation for epidermolysis bullosa. A productive Type B pre-IND meeting with the FDA furthered its development. Additionally, RLF-OD032, a next-generation liquid sapropterin formulation for phenylketonuria, is poised to enter a pivotal trial this quarter.

The company projects that its current cash reserves will fund operations into late 2026, past the targeted U.S. regulatory submission for RLF-OD032. Moreover, Relief is preparing to establish an AI-driven health tech company through a potential business combination with NeuroX. The half-year report, including financial statements for the period ending June 30, 2025, is available on the company’s website.